Multiregion human bladder cancer sequencing reveals tumour evolution, bladder cancer phenotypes and implications for targeted therapy.
Aged
Aged, 80 and over
Biomarkers, Tumor
/ genetics
Carcinoma
/ drug therapy
Carcinoma in Situ
/ drug therapy
Cystectomy
DNA Copy Number Variations
Disease Progression
Female
Gene Dosage
Genetic Heterogeneity
Genetic Predisposition to Disease
Humans
Male
Middle Aged
Molecular Targeted Therapy
Mutation
Neoplasm Invasiveness
Phenotype
Ploidies
Precision Medicine
Time Factors
Transcriptome
Urinary Bladder Neoplasms
/ drug therapy
Exome Sequencing
bladder cancer
kataegis
phylogenetic analysis
tumour evolution
tumour heterogeneity
tumour phenotype
Journal
The Journal of pathology
ISSN: 1096-9896
Titre abrégé: J Pathol
Pays: England
ID NLM: 0204634
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
14
04
2018
revised:
27
01
2019
accepted:
30
01
2019
pubmed:
6
2
2019
medline:
14
4
2020
entrez:
6
2
2019
Statut:
ppublish
Résumé
We present an evolutionary analysis of the relative time of genetic events underlying tumorigenesis in human bladder cancers from 10 whole cystectomy specimens using multiregional whole-exome sequencing. We timed bladder cancer drivers, mutational signatures, ploidy and copy number alterations, provided evidence for kataegis and correlated alterations with tumour areas and histological phenotypes. We found that: (1) heterogeneous tumour areas/phenotypes had distinct driver mutations, (2) papillary-invasive tumours divided early into two parallel evolving branches and (3) parallel evolution of subclonal driver mutations occurred. APOBEC mutational signatures were found to be very early events, active in carcinoma in situ, and often remained a dominant source of mutations throughout tumour evolution. Genetic progression from carcinoma in situ followed driver mutations in NA13/FAT1, ZBTB7B or EP300/USP28/KMT2D. Our results point towards a more diverse mutational trajectory of bladder tumorigenesis and underpin the importance of timing of mutational processes and clonal architecture in bladder cancer as important aspects for successful prognostication and therapy. Copyright © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
230-242Subventions
Organisme : Cancer Research UK
ID : A19771
Pays : United Kingdom
Informations de copyright
Copyright © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.